Improving access to radiotheranostics for cancer patients in the US

THE CARY M. ADAMS FUND
Recent research and developments have shown the promising outcomes regarding the use of radiotheranostics in the cancer care landscape, with some approved products* already on the market and others in early-stage development or clinical trials. However, availability of these treatments, education and awareness of the potential use of such therapies is still very limited.

Considering these opportunities and challenges, it is in this context that the Oncidium foundation, together with Cary's wife and daughters, have decided to open the "Cary M. Adams Fund", in honor of their late husband and father, Mr. Cary M. Adams, a firm believer in the potential of radiotheranostics-based treatments for cancer care, to support cancer patients access to radiotheranostics in the US.
(* In the US, 177-Lutetium vipivotide tetraxetan was approved on March 2022, by the Food and Drug Administration for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)).

CARY M. ADAMS September 5, 1948 - September 9, 2022
Cary was an attorney & investor with an entrepreneurial spirit, a passion for innovation, and an unquenchable thirst for knowledge. Despite his many professional pursuits, Cary's family and community always came first. In Cary's final years, he became both an advocate for & participant in research of radiotheranostic cancer treatments.

THE ONCIDIUM FOUNDATION
The Oncidium foundation is a non-profit, public benefit organization that aims to support and accelerate the development of radiotheranostics for cancer care, worldwide. For more information, visit the Oncidium foundation website: www.oncidiumfoundation.org